Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance

The Single Oral Favipiravir for Patients with Delayed SARS-Cov-2 viral RNA Clearance

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033491

Enrollment

Unknown

Registered

2020-06-02

Start date

2020-02-11

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:oral Favipiravir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or non-pregnant female, aged 18-75 years; 2. With sustained positive detection of SARS-CoV-2 viral RNA in the upper respiratory tract for above 28 days; 3. The last time detection of viral RNA by a designated diagnostic laboratory was positive before inclusion;

Exclusion criteria

Exclusion criteria: 1. Severe vomiting or intolerance of oral drug for other reasons; 2. Pregnancy or breast-feeding; 3. Known allergy or hypersensitivity to favipiravir.

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 viral RNA PCR test;	—

Countries

China

Contacts

Public ContactJiqiu Wen

Jinling Hospital, Nanjing University School of Medicine

wjqkidney@hotmail.com+86 13851767588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026